AKERO THERAPEUTICS, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.08 USD | +0.28% |
|
+20.19% | -1.22% |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 1.59B |
|---|---|---|---|---|---|
| Net income 2024 * | -240M | Net income 2025 * | -284M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 725M | Net cash position 2025 * | 476M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-6.06
x | P/E ratio 2025 * |
-5.3
x | Employees | 59 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 84.99% |
More Fundamentals
* Assessed data
More news
Latest transcript on Akero Therapeutics, Inc.
More recommendations
More press releases
More news
| 1 day | +7.92% | ||
| 1 week | +22.32% | ||
| Current month | +22.32% | ||
| 1 month | +10.67% | ||
| 3 months | -26.17% | ||
| 6 months | +15.85% | ||
| Current year | -1.41% |
1 week
17.86
24.39
1 month
17.8624.39
Current year
15.3237.00
1 year
11.2558.38
3 years
7.5258.38
5 years
7.5258.38
10 years
7.5258.38
| Managers | Title | Age | Since |
|---|---|---|---|
Jonathan Young
FOU | Founder | 54 | 17-03-31 |
Timothy Rolph
FOU | Founder | 70 | 17-03-31 |
Andrew Cheng
CEO | Chief Executive Officer | 57 | 18-08-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Seth Harrison
BRD | Director/Board Member | 63 | 16-12-31 |
Jane Henderson
BRD | Director/Board Member | 58 | 19-04-22 |
Mark Iwicki
CHM | Chairman | 57 | 18-10-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.18% | 0 M€ | 0.00% | - | |
| 0.12% | 248 M€ | +11.05% | - | |
| 0.10% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-10 | 23.08 | +0.28% | 663 653 |
| 24-06-07 | 23.02 | +7.92% | 1,543,229 |
| 24-06-06 | 21.33 | +2.60% | 919,058 |
| 24-06-05 | 20.79 | +8.17% | 1,516,812 |
| 24-06-04 | 19.22 | +0.16% | 951,346 |
Delayed Quote Nasdaq, June 07, 2024 at 04:00 pm EDT
More quotes
Akero Therapeutics, Inc. is a clinical-stage company. The Company is developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH), a disease without any approved therapies. Efruxifermin (EFX), is its lead product candidate for MASH, which is being evaluated in the ongoing phase IIb SYMMETRY, phase III SYNCHRONY Histology, and phase III SYNCHRONY real-world studies. The phase III SYNCHRONY program builds on the results of two phase IIb clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with cirrhosis due to MASH. EFX is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. EFX is designed to offer convenient once-weekly dosing.
Calendar
2024-08-12
- Q2 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
23.02
USD
Average target price
45.12
USD
Spread / Average Target
+96.03%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -1.41% | 1.59B | |
| +18.72% | 125B | |
| +14.19% | 108B | |
| -4.93% | 24.21B | |
| +0.87% | 22.78B | |
| -10.72% | 17.96B | |
| -41.74% | 16.43B | |
| -13.31% | 16.37B | |
| +2.44% | 13.58B | |
| +27.89% | 11.66B |
- Stock Market
- Equities
- AKRO Stock
